739 results on '"Suzuki, Shigeaki"'
Search Results
2. Taste disorders and alopecia in myasthenia gravis
3. Worsening of myasthenic symptoms associated with statins
4. Dysautonomia associated with immune checkpoint inhibitors
5. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis
6. Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan
7. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
8. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
9. Proteolytic ectodomain shedding of muscle-specific tyrosine kinase in myasthenia gravis
10. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies
11. Pathologic Features of Anti-Ku Myositis
12. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature
13. Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
14. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
15. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
16. Clinical characteristics of human herpesvirus-6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention
17. Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the phase III randomized RAISE study.
18. Efficacy and safety of zilucoplan in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the phase III randomized RAISE study
19. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial
20. Two-year changes of bone mineral density in steroid-treated myasthenia gravis
21. Association Between HLA Alleles and Autoantibodies in Dermatomyositis Defined by Sarcoplasmic Expression of Myxovirus Resistance Protein A
22. Overlap syndrome with antibodies against multiple transfer-RNA components presenting antisynthetase syndrome
23. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
24. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
25. Muscle pathology of antisynthetase syndrome according to antibody subtypes
26. Increased risk of Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer patients treated with immune checkpoint inhibitor
27. Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors
28. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis
29. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome
30. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis
31. Association of immune‐mediated necrotizing myopathy with HLA polymorphisms
32. Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study
33. Hyponatremia associated with human herpesvirus-6 (HHV-6) encephalitis after allogeneic hematopoietic stem cell transplantation: A presentation different from HHV-6 myelitis
34. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective
35. Japan MG registry: Chronological surveys over 10 years
36. Immunodeficiency in patients with thymoma-associated myasthenia gravis
37. Anemia in female patients with myasthenia gravis
38. Immunohistochemical Phenotype of T Cells Invading Muscle in Inclusion Body Myositis
39. Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies
40. Rationale for the clinical guidelines for myasthenia gravis in Japan
41. New Criteria Needed for Antisynthetase Syndrome—Reply
42. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review
43. Diagnosis of dermatomyositis: Autoantibody profile and muscle pathology
44. Inflammatory myopathies and human leukocyte antigen
45. Recent progress in inflammatory myopathies: Contributions of young Japanese investigators
46. A clinical predictive score for postoperative myasthenic crisis
47. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) after treatment for Hodgkin’s lymphoma
48. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Analysis of 1‐year postmarketing surveillance
49. Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data (S41.009)
50. Flare of myasthenia gravis induced by COVID-19 vaccines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.